FDA 483 - Bora Pharmaceutical Services Inc. - January 28, 2025

This request for a concise summary of an FDA 483 document cannot be fulfilled as the actual content of the document was not provided. The input consisted solely of page numbers without any textual information regarding the inspection findings. If the detailed FDA Form 483 had been supplied, the summary would typically identify the inspected company and the specific inspection dates. It would then meticulously outline the main observations or issues identified by the FDA investigators. These issues commonly pertain to deficiencies in the company's quality management system, manufacturing processes, laboratory controls, facility maintenance, or data integrity practices, indicating non-compliance with current Good Manufacturing Practices (cGMP) or other relevant regulations. The regulatory framework, such as 21 CFR Part 211 for pharmaceutical products or 21 CFR Part 820 for medical devices, would underpin these observations. Finally, the summary would implicitly highlight the company's obligation to promptly address these findings by developing and implementing robust corrective and preventive actions (CAPA) and submitting a comprehensive response to the FDA within a stipulated timeframe, demonstrating their commitment to regulatory compliance and product quality. Without the specific details, a substantive summary is impossible.